TAMIFLU Drug Patent Profile
✉ Email this page to a colleague
When do Tamiflu patents expire, and when can generic versions of Tamiflu launch?
Tamiflu is a drug marketed by Roche and is included in two NDAs.
The generic ingredient in TAMIFLU is oseltamivir phosphate. There are eight drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tamiflu
A generic version of TAMIFLU was approved as oseltamivir phosphate by NATCO on August 3rd, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TAMIFLU?
- What are the global sales for TAMIFLU?
- What is Average Wholesale Price for TAMIFLU?
Summary for TAMIFLU
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Clinical Trials: | 71 |
Patent Applications: | 2,963 |
Drug Prices: | Drug price information for TAMIFLU |
Drug Sales Revenues: | Drug sales revenues for TAMIFLU |
What excipients (inactive ingredients) are in TAMIFLU? | TAMIFLU excipients list |
DailyMed Link: | TAMIFLU at DailyMed |
Recent Clinical Trials for TAMIFLU
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Hospital of Philadelphia | Phase 4 |
Weill Medical College of Cornell University | Phase 4 |
Genentech, Inc. | Phase 4 |
Pharmacology for TAMIFLU
Drug Class | Neuraminidase Inhibitor |
Mechanism of Action | Neuraminidase Inhibitors |
Paragraph IV (Patent) Challenges for TAMIFLU
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TAMIFLU | for Oral Suspension | oseltamivir phosphate | 6 mg/mL | 021246 | 1 | 2015-06-18 |
TAMIFLU | Capsules | oseltamivir phosphate | 30 mg and 45 mg | 021087 | 1 | 2011-08-02 |
TAMIFLU | Capsules | oseltamivir phosphate | 75 mg | 021087 | 1 | 2010-11-15 |
US Patents and Regulatory Information for TAMIFLU
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Roche | TAMIFLU | oseltamivir phosphate | CAPSULE;ORAL | 021087-003 | Jul 2, 2007 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Roche | TAMIFLU | oseltamivir phosphate | FOR SUSPENSION;ORAL | 021246-002 | Mar 21, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Roche | TAMIFLU | oseltamivir phosphate | CAPSULE;ORAL | 021087-002 | Jul 2, 2007 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Roche | TAMIFLU | oseltamivir phosphate | CAPSULE;ORAL | 021087-001 | Oct 27, 1999 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Roche | TAMIFLU | oseltamivir phosphate | FOR SUSPENSION;ORAL | 021246-001 | Dec 14, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TAMIFLU
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Roche | TAMIFLU | oseltamivir phosphate | CAPSULE;ORAL | 021087-002 | Jul 2, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Roche | TAMIFLU | oseltamivir phosphate | FOR SUSPENSION;ORAL | 021246-002 | Mar 21, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Roche | TAMIFLU | oseltamivir phosphate | CAPSULE;ORAL | 021087-003 | Jul 2, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Roche | TAMIFLU | oseltamivir phosphate | FOR SUSPENSION;ORAL | 021246-001 | Dec 14, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Roche | TAMIFLU | oseltamivir phosphate | FOR SUSPENSION;ORAL | 021246-002 | Mar 21, 2011 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TAMIFLU
See the table below for patents covering TAMIFLU around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 101143859 | ⤷ Sign Up | |
Denmark | 0976734 | ⤷ Sign Up | |
China | 1733707 | ⤷ Sign Up | |
Hungary | 229200 | Selective inhibitors of viral or bacterial neuraminidase | ⤷ Sign Up |
Norway | 973908 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TAMIFLU
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0759917 | CA 2002 00027 | Denmark | ⤷ Sign Up | |
0759917 | 90991 | Luxembourg | ⤷ Sign Up | |
0759917 | SPC031/2002 | Ireland | ⤷ Sign Up | SPC031/2002: 20021107, EXPIRES: 20160226 |
0759917 | 38/2002 | Austria | ⤷ Sign Up | PRODUCT NAME: OSELTAMIVIR PHOSPHAT; REGISTRATION NO/DATE: EU/1/02/222/001 EU/1/02/222/002 20020620 |
0759917 | 0290024-9 | Sweden | ⤷ Sign Up | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |